[
  {
    "date": "2023-06-30",
    "symbol": "BNOX",
    "period": "FY",
    "documenttype": "20-F",
    "amendmentflag": "false",
    "documentperiodenddate": "2023-06-30",
    "documentfiscalyearfocus": 2023,
    "documentfiscalperiodfocus": "FY",
    "entityregistrantname": "BIONOMICS LIMITED/FI",
    "entitycentralindexkey": 1191070,
    "entitycurrentreportingstatus": "Yes",
    "entityvoluntaryfilers": "No",
    "entityinteractivedatacurrent": "Yes",
    "currentfiscalyearenddate": "--06-30",
    "entityfilercategory": "Non-accelerated Filer",
    "entitywellknownseasonedissuer": "No",
    "entitycommonstocksharesoutstanding": 1486735424,
    "entityshellcompany": "false",
    "entityemerginggrowthcompany": "true",
    "entityextransitionperiod": "false",
    "entityfilenumber": "001-41157",
    "entityincorporationstatecountrycode": "C3",
    "entityaddressaddressline1": "200 Greenhill Road",
    "entityaddressaddressline2": "Suite 150N",
    "entityaddresscityortown": "Eastwood SA",
    "entityaddresspostalzipcode": 5063,
    "entityaddresscountry": "AU",
    "documentannualreport": "true",
    "documenttransitionreport": "false",
    "documentshellcompanyreport": "false",
    "documentregistrationstatement": "false",
    "documentaccountingstandard": "International Financial Reporting Standards",
    "icfrauditorattestationflag": "false",
    "auditorname": "Ernst & Young",
    "auditorfirmid": 1435,
    "auditorlocation": "Adelaide, Australia",
    "cityareacode": 61,
    "localphonenumber": "8 881507400",
    "tradingsymbol": "BNOX",
    "security12btitle": "American Depository Shares, each representing the right to receive one hundred eighty (180) Ordinary Shares, no par value per share",
    "securityexchangename": "NASDAQ",
    "contactpersonnelname": "Spyridon “Spyros” Papapetropoulos, M.D.",
    "contactpersonnelemailaddress": "spyros@bionomics.com.au",
    "documentfinstmterrorcorrectionflag": "false",
    "revenue": 22047,
    "revenuefrominterest": 479726,
    "otherincome": 627558,
    "othergainslosses": -529690,
    "researchanddevelopmentexpense": 19613270,
    "administrativeexpense": 8636180,
    "occupancyexpense": 220344,
    "complianceexpenses": 4154366,
    "financecosts": 29230,
    "profitlossbeforetax": -32053749,
    "incometaxexpensecontinuingoperations": -206792,
    "profitloss": -31846957,
    "reclassificationadjustmentsonexchangedifferencesontranslationnetoftax": -460506,
    "comprehensiveincome": -31386451,
    "basicearningslosspersharefromcontinuingoperations": -0.02,
    "dilutedearningslosspersharefromcontinuingoperations": -0.02,
    "cashandcashequivalents": 18250255,
    "tradeandothercurrentreceivables": 14718,
    "researchanddevelopmentincentivesreceivable": 627559,
    "othercurrentnonfinancialassets": 1203214,
    "currentassets": 20095746,
    "propertyplantandequipment": 3804,
    "rightofuseassets": 498458,
    "goodwill": 13084300,
    "intangibleassetsotherthangoodwill": 9202594,
    "othernoncurrentnonfinancialassets": 119000,
    "noncurrentassets": 22908156,
    "assets": 43003902,
    "tradeandothercurrentpayables": 3500487,
    "currentleaseliabilities": 171841,
    "currentprovisions": 457017,
    "currentliabilities": 4129345,
    "noncurrentleaseliabilities": 361742,
    "noncurrentprovisions": 22398,
    "deferredtaxliabilities": 1655369,
    "contingentconsideration": 3687189,
    "noncurrentliabilities": 5726698,
    "liabilities": 9856043,
    "netassetsliabilities": 33147859,
    "issuedcapital": 223412662,
    "otherreserves": 14505746,
    "accumulatedothercomprehensiveincome": -204770549,
    "equity": 33147859,
    "gainslossesonexchangedifferencesontranslationnetoftax": 460506,
    "increasedecreasethroughsharebasedpaymenttransactions": 1904553,
    "transferofexpiredoptionsandwarrants": -382911,
    "issueofordinarysharesasresultofusf1": 7419235,
    "shareissuerelatedcost": 1702332,
    "shareissuedexpensebenefit": -1702332,
    "researchanddevelopmentincentivesreceived": 6719760,
    "receiptsfromsalesofgoodsandrenderingofservices": 22047,
    "paymentstosuppliersforgoodsandservicesandtoandonbehalfofemployees": 28055945,
    "interestpaidclassifiedasoperatingactivities": 29230,
    "cashflowsfromusedinoperatingactivities": -21343368,
    "interestreceivedclassifiedasinvestingactivities": 479528,
    "cashflowsfromusedininvestingactivities": 479528,
    "paymentsofleaseliabilitiesclassifiedasfinancingactivities": 160040,
    "proceedsfromissuingshares": 7419235,
    "paymentsforshareissuecosts": 1702332,
    "cashflowsfromusedinfinancingactivities": 5556863,
    "increasedecreaseincashandcashequivalentsbeforeeffectofexchangeratechanges": -15306977,
    "effectofexchangeratechangesoncashandcashequivalents": -7625,
    "addressofregisteredofficeofentity": "200 Greenhill Road",
    "principalplaceofbusiness": "Eastwood, South Australia, 5063",
    "employeebenefitsexpense": 5866810,
    "descriptionofvestingrequirementsforsharebasedpaymentarrangement": "five years",
    "usefullifemeasuredasperiodoftimeintangibleassetsotherthangoodwill": "P15Y",
    "usefullifeofrighttouseassets": "P5Y",
    "depreciationratepropertyplantandequipment": 0.2,
    "revenuefromcontractswithcustomers": 22047,
    "governmentresearchanddevelopmentincentives": 627558,
    "otheroperatingincomeexpense": 627558,
    "taxrateeffectfromchangeintaxrate": 0.435,
    "annualrevenueeligibleforgovernmentgrants": 20000000,
    "gainlossfromchangesinfairvalueofcontingentconsideration": -988179,
    "netrealisedandunrealisedforeigncurrencygains": 458489,
    "interestexpenseonleaseliabilities": 21278,
    "bankandsimilarcharges": 7952,
    "wagesandsalaries": 3785547,
    "superannuation": 176710,
    "adjustmentsforsharebasedpayments": 1904553,
    "depreciationpropertyplantandequipment": 1368,
    "depreciationrightofuseassets": 170900,
    "amortisationintangibleassetsotherthangoodwill": 984724,
    "depreciationandamortisationexpense": 1156992,
    "minimumleasepayments": 5729,
    "deferredtaxexpenseincome": -206792,
    "deferredtaxexpenseincomerecognisedinprofitorloss": -206792,
    "accountingprofit": -32053749,
    "taxexpenseincomeatapplicabletaxrate": -8013437,
    "taxeffectofrevenuesexemptfromtaxation2011": 156890,
    "taxeffectofentertainmentexpenses": 1448,
    "taxeffectnetgainarisingonchangesinfairvalueofcontingentconsideration": 247045,
    "taxeffectofsharebasedpayments": 476138,
    "taxeffectofresearchanddevelopmentexpenditure": 360666,
    "taxeffectofamortisationofshareissuecosts": -285631,
    "temporarydifferencesforwhichnodeferredtaxassetrecognised": -787392,
    "taxlossesnotrecorded": 7872870,
    "taxeffectofforeigntaxrates": 78391,
    "applicabletaxrate": 0.25,
    "taxeffectsofintangibles": -1932546,
    "taxeffectsoftaxlosses": 277177,
    "deferredtaxliabilityasset": -1655369,
    "deferredtaxliabilityrecognisedinincome": 206792,
    "deferredtaxrelatingtoitemschargedorcrediteddirectlytoequity": -63536,
    "deferredtaxassetsnotrecognisedrevenuetaxloss": 33323740,
    "increasedecreaseindeferredtaxliabilityassets": 2387515,
    "netdeferredtaxassetsnotrecognised": 35711255,
    "cash": 18250255,
    "weightedaverageinterestrateondeposits": 0.032,
    "restricteddeposits": 119000,
    "othernoncurrentfinancialassets": 119000,
    "otherfinancialassets": 119000,
    "restricteddepositmaturitydate": "2024-06-03",
    "effectiveinterestratesondeposits": 0.042,
    "othercurrentreceivables": 886,
    "tradeandothercurrentreceivablesbeforetax": 886,
    "gstreceivables": 13832,
    "currentprepayments": 1202826,
    "currentaccruedincomeincludingcurrentcontractassets": 388,
    "othercurrentassets": 1203214,
    "nameofsubsidiary": "Iliad Chemicals Pty Ltd",
    "principalactivity": "Research and Development",
    "countryofincorporation": "Australia",
    "countryofincorporationorresidenceofsubsidiary": "Australia",
    "proportionofownershipinterestinsubsidiary": 1,
    "increasedecreasethroughnetexchangedifferencesgoodwill": 216178,
    "descriptionofbasisonwhichunitsrecoverableamounthasbeendetermined": "The recoverable amount of the drug development CGU is determined based on a value in use calculation which uses cash flow projections based on observable market comparables for drug compounds within the CGU over a period of twenty years covering drug discovery, development, approval and marketing, and a post-tax discount rate of 18.5% (2022: 17%).",
    "descriptionofdiscountratesappliedtocashflowprojections": 0.185,
    "increasedecreasethroughnetexchangedifferencesintangibleassetsotherthangoodwill": 700873,
    "intangibleassetsandgoodwill": 9202594,
    "tradeandothercurrentpayablestotradesuppliers": 2062549,
    "accrualsclassifiedascurrent": 1437938,
    "averagecreditperiodonpurchasesofgoods": "P45D",
    "leaseliabilities": 533583,
    "repayments": -160040,
    "interestelementofleasepaymentscontinuingoperations": 21278,
    "cashoutflowforleases": 181318,
    "undiscountedoperatingleasepaymentstobereceived": 1183105,
    "currentprovisionsforemployeebenefits": 457017,
    "noncurrentprovisionsforemployeebenefits": 22398,
    "numberofsharesissued": 1468735424,
    "issuedcapitalordinaryshares": 223412662,
    "numberofordinarysharesissedinipof1shareplacement": 115384680,
    "issueofordinarysharesinipof1shareplacement": 7419235,
    "weightedaverageshareprice2019": 0.24,
    "parvaluepershare": 0.2513,
    "numberofotherequityinstrumentsexercisableinsharebasedpaymentarrangement": 46690480,
    "weightedaverageremainingcontractuallifeofoutstandingshareoptions2019": "P0Y1M28D",
    "weightedaverageremainingcontractuallifeofoutstandingstockoption": "P4Y10M6D",
    "numberofoutstandingshareoptions": 117211315,
    "numberofshareoptionsgrantedinsharebasedpaymentarrangement": 43100348,
    "numberofshareoptionsforfeitedinsharebasedpaymentarrangement": 3500000,
    "numberofshareoptionsexpiredinsharebasedpaymentarrangement": 1445650,
    "weightedaverageexercisepriceofshareoptionsoutstandinginsharebasedpaymentarrangement2019": 0.12,
    "weightedaverageexercisepriceofshareoptionsgrantedinsharebasedpaymentarrangement2019": 0.04,
    "weightedaverageexercisepriceofshareoptionsforfeitedinsharebasedpaymentarrangement2019": 0.05,
    "weightedaverageexercisepriceofshareoptionsexpiredinsharebasedpaymentarrangement2019": 0.39,
    "dateofgrantofsharebasedpaymentarrangement": "26-Aug-20",
    "exercisepriceofoutstandingshareoptions2019": 0.04,
    "descriptionofriskfreeinterestrateshareoptionsgranted": 0.0042,
    "descriptionofexpectedvolatilityshareoptionsgranted": 1.05,
    "sharebasedpaymentsarrangementexpirationdate": "2023-08-26",
    "grantdatesharebasedpayment": "2015-07-20",
    "sharebasedpaymentsarrangementexpirationdates": "2023-07-20",
    "numberofotherequityinstrumentsoutstandinginsharebasedpaymentarrangement": 142000000,
    "weightedaverageexercisepriceofotherequityinstrumentsoutstandinginsharebasedpaymentarrangement2019": 0.06,
    "reserveofexchangedifferencesontranslation": 6646840,
    "reserveofsharebasedpayments": 7858906,
    "tradereceivables": 642277,
    "financialassets": 19011532,
    "tradeandotherpayables": 3500487,
    "financialliabilities": 7721259,
    "foreigncurrencysensitivityrate": 0.1,
    "monetaryitemsnet": -3586151,
    "otherintangibleassets": 9202594,
    "nonmonetaryitemsnet": 13684430,
    "foreigncurrencyrisk": 10098279,
    "gainslossesonexchangedifferencesontranslationrecognisedinprofitorlossduetotenpercentincrease": -579305,
    "gainslossesonexchangedifferencesontranslationrecognisedinequityduetotenpercentincrease": 91097,
    "gainslossesonexchangedifferencesontranslationrecognisedinprofitorlossduetotenpercentdecrease": 579305,
    "gainslossesonexchangedifferencesontranslationrecognisedinequityduetotenpercentdecrease": -91097,
    "weightedaverageeffectiveinterestrate": 0.0356,
    "tradeandotherpayablesundiscountedcashflows": 3500487,
    "grossleaseliabilities": 15564,
    "nonderivativefinancialliabilitiesundiscountedcashflows": 3516051,
    "contingentconsiderationrecognisedasofacquisitiondate": 3687189,
    "descriptionofvaluationtechniquesusedinfairvaluemeasurementliabilities": "Discounted cash flow",
    "descriptionofinputsusedinfairvaluemeasurementliabilities": "Discount rate of 25% (pre-tax) and probability adjusted revenue projections.",
    "descriptionofrelationshipofunobservableinputstofairvaluemeasurementliabilities": "The higher the discount rate, the lower the value.  The higher the possible revenue the higher value.",
    "increasedecreaseinfairvaluemeasurementliabilities": 988179,
    "keymanagementpersonnelcompensationshorttermemployeebenefits": 3717144,
    "keymanagementpersonnelcompensationpostemploymentbenefits": 71876,
    "keymanagementpersonnelcompensationotherlongtermbenefits": 33133,
    "keymanagementpersonnelcompensationsharebasedpayment": 1899827,
    "keymanagementpersonnelcompensation": 5721980,
    "operatingleaseterm": "P3Y",
    "noncancellableoperatingleasecommitment": 5469,
    "auditorsremunerationforauditservices": 357500,
    "auditorsremuneration": 500500,
    "adjustmentsfordepreciationandamortisationexpense": 1156992,
    "adjustmentsforfairvaluegainslosses": 988179,
    "adjustmentsforunrealisedforeignexchangelossesgains": -33555,
    "interestreceivedclassifiedasoperatingactivities": 479726,
    "adjustmentsfordecreaseincreaseintradeaccountreceivable": 49642,
    "adjustmentsfordecreaseincreaseinresearchanddevelopmentincentivereceivable": -6092202,
    "adjustmentsfordecreaseincreaseinotherassets": 258252,
    "adjustmentsforincreasedecreaseintradeaccountpayable": 714207,
    "adjustmentsforprovisions": 59635,
    "adjustmentsfordeferredtaxexpense": -206792,
    "basicearningslosspershare": -0.02,
    "dilutedearningslosspershare": -0.02,
    "profitlossfromcontinuingoperations": -31846957,
    "weightedaverageshares": 1468735424,
    "dilutiveeffectofshareoptionsonnumberofordinaryshares": 46690480,
    "dilutiveeffectofconvertibleinstrumentsonnumberofordinaryshares": 142000000,
    "numberofpotentialantidilutiveordinarysharesexcludedfromcomputationoflosspershare": -46690480,
    "adjustedweightedaverageshares": 1468735424,
    "explanationoftheemploymentcontract": "On 5 January 2023, Dr Spyros Papapetropoulos commenced employment as President and Chief Executive Officer, details of the employment contract are set out below:",
    "agreedtransitionalpayable": 351376,
    "bonuspayable": 332325,
    "increasedecreaseincontingentconsiderationassetliability": 988179,
    "rentguarantee": 119000,
    "contingentliabilitypayable": 787500,
    "contingentliabilitypaid": 683701
  },
  {
    "date": "2022-06-30",
    "symbol": "BNOX",
    "period": "FY",
    "documenttype": "20-F",
    "amendmentflag": "false",
    "documentperiodenddate": "June 30, 2022",
    "documentfiscalyearfocus": 2022,
    "documentfiscalperiodfocus": "FY",
    "entityregistrantname": "BIONOMICS LIMITED/FI",
    "entitycentralindexkey": 1191070,
    "entitycurrentreportingstatus": "Yes",
    "entityvoluntaryfilers": "No",
    "entityinteractivedatacurrent": "Yes",
    "currentfiscalyearenddate": "--06-30",
    "entityfilercategory": "Non-accelerated filer",
    "entitywellknownseasonedissuer": "No",
    "entitycommonstocksharesoutstanding": "null",
    "entityshellcompany": "true",
    "entityemerginggrowthcompany": "true",
    "entityextransitionperiod": "false",
    "entityfilenumber": "001-41157",
    "entityincorporationstatecountrycode": "Australia",
    "entityaddressaddressline1": "2710 Gateway Oaks Drive",
    "entityaddressaddressline2": "Suite 150N",
    "entityaddresscityortown": "Sacramento",
    "entityaddresspostalzipcode": 95833,
    "entityaddresscountry": "CA",
    "documentannualreport": "true",
    "documenttransitionreport": "false",
    "documentshellcompanyreport": "false",
    "documentregistrationstatement": "false",
    "documentaccountingstandard": "International Financial Reporting Standards",
    "icfrauditorattestationflag": "false",
    "auditorname": "Ernst & Young (2020: Deloitte Touche Tohmatsu)",
    "auditorfirmid": 1435,
    "auditorlocation": "Adelaide, Australia",
    "cityareacode": 61,
    "localphonenumber": "8 881507400",
    "tradingsymbol": "BNOX",
    "security12btitle": "American Depository Shares, each representing the right to receive one hundred eighty (180) Ordinary Shares, no par value per share",
    "securityexchangename": "The Nasdaq Global Market",
    "contactpersonnelname": "Errol De Souza, Ph.D.",
    "contactpersonnelemailaddress": "edesouza@bionomics.com.au",
    "revenue": 263634,
    "otherincome": "null",
    "othergainslosses": -582015,
    "researchanddevelopmentexpense": "null",
    "administrativeexpense": "null",
    "occupancyexpense": 262440,
    "complianceexpenses": "null",
    "financecosts": 44165,
    "profitlossbeforetax": "-null",
    "incometaxexpensecontinuingoperations": -191808,
    "profitlossfromcontinuingoperations": "-null",
    "profitloss": "-null",
    "reclassificationadjustmentsonexchangedifferencesontranslationnetoftax": "-null",
    "comprehensiveincome": "-null",
    "basicearningslosspersharefromcontinuingoperations": -0.02,
    "dilutedearningslosspersharefromcontinuingoperations": -0.02,
    "cashandcashequivalents": "null",
    "tradeandothercurrentreceivables": 64360,
    "researchanddevelopmentincentivesreceivable": "null",
    "othercurrentnonfinancialassets": "null",
    "currentassets": "null",
    "propertyplantandequipment": 5172,
    "rightofuseassets": 669358,
    "goodwill": "null",
    "intangibleassetsotherthangoodwill": "-null",
    "othernoncurrentnonfinancialassets": 119000,
    "noncurrentassets": "null",
    "assets": "null",
    "tradeandothercurrentpayables": "null",
    "currentleaseliabilities": 160040,
    "currentprovisions": 409320,
    "currentliabilities": "null",
    "noncurrentleaseliabilities": 533583,
    "noncurrentprovisions": 10460,
    "deferredtaxliabilities": "null",
    "contingentconsideration": "-null",
    "noncurrentliabilities": "null",
    "liabilities": "null",
    "netassetsliabilities": "null",
    "issuedcapital": "null",
    "otherreserves": "null",
    "accumulatedothercomprehensiveincome": "-null",
    "equity": "-null",
    "gainslossesonexchangedifferencesontranslationnetoftax": "null",
    "increasedecreasethroughsharebasedpaymenttransactions": "null",
    "transferofexpiredoptionsandwarrants": "null",
    "issueofordinarysharesundershareplacements": 27200,
    "issueofordinarysharesunderrightsissues": 480000,
    "transferfromsharebasedpaymentsreserve": -327760,
    "issueofordinarysharesasresultofusipo": "null",
    "shareissuerelatedcost": "null",
    "shareissuedexpensebenefit": "-null",
    "receiptsfromsalesofgoodsandrenderingofservices": 270975,
    "paymentstosuppliersforgoodsandservicesandtoandonbehalfofemployees": "null",
    "interestpaidclassifiedasoperatingactivities": 44165,
    "cashflowsfromusedinoperatingactivities": "-null",
    "interestreceivedclassifiedasinvestingactivities": 12516,
    "proceedsfromsalesormaturityoffinancialinstrumentsclassifiedasinvestingactivities": 435640,
    "purchaseofpropertyplantandequipmentclassifiedasinvestingactivities": 1544,
    "proceedsfromsalesofpropertyplantandequipmentclassifiedasinvestingactivities": 175091,
    "cashflowsfromusedininvestingactivities": 621703,
    "paymentsofleaseliabilitiesclassifiedasfinancingactivities": 174218,
    "proceedsfromissuingshares": "null",
    "paymentsforshareissuecosts": "null",
    "cashflowsfromusedinfinancingactivities": "null",
    "increasedecreaseincashandcashequivalentsbeforeeffectofexchangeratechanges": "null",
    "effectofexchangeratechangesoncashandcashequivalents": -796430,
    "addressofregisteredofficeofentity": "200 Greenhill Road",
    "principalplaceofbusiness": "Eastwood, South Australia, 5063",
    "employeebenefitsexpense": "null",
    "descriptionofvestingrequirementsforsharebasedpaymentarrangement": "five years",
    "usefullifemeasuredasperiodoftimeintangibleassetsotherthangoodwill": 20,
    "usefullifeofrighttouseassets": 5,
    "depreciationratepropertyplantandequipment": 0.4,
    "numberofoperatingsegment": 1,
    "revenuefromcontractswithcustomers": 263634,
    "revenuefrominterest": 9869,
    "rentalincome": 6674,
    "governmentresearchanddevelopmentincentives": "null",
    "otheroperatingincomeexpense": "null",
    "taxrateeffectfromchangeintaxrate": 0.435,
    "annualrevenueeligibleforgovernmentgrants": 20000000,
    "gainlossfromchangesinfairvalueofcontingentconsideration": -936354,
    "netrealisedandunrealisedforeigncurrencygains": 356166,
    "gainslossesondisposalsofpropertyplantandequipment": -1827,
    "interestexpenseonleaseliabilities": 26872,
    "bankandsimilarcharges": 17293,
    "wagesandsalaries": "null",
    "superannuation": 266127,
    "adjustmentsforsharebasedpayments": "null",
    "depreciationpropertyplantandequipment": 2681,
    "depreciationrightofuseassets": 193358,
    "amortisationintangibleassetsotherthangoodwill": -913373,
    "depreciationandamortisationexpense": 193358,
    "minimumleasepayments": 5260,
    "deferredtaxexpenseincome": -191808,
    "deferredtaxexpenseincomerecognisedinprofitorloss": -191808,
    "accountingprofit": "-null",
    "taxexpenseincomeatapplicabletaxrate": "-null",
    "taxeffectofrevenuesexemptfromtaxation2011": "null",
    "taxeffectofentertainmentexpenses": 1231,
    "taxeffectnetgainarisingonchangesinfairvalueofcontingentconsideration": 234089,
    "taxeffectofsharebasedpayments": 707422,
    "taxeffectofresearchanddevelopmentexpenditure": "null",
    "taxeffectofamortisationofshareissuecosts": -285631,
    "temporarydifferencesforwhichnodeferredtaxassetrecognised": -58374,
    "taxlossesnotrecorded": "null",
    "taxeffectofforeigntaxrates": 37066,
    "applicabletaxrate": 0.25,
    "taxeffectofintangibles": "-null",
    "taxeffectoftaxlosses": 267412,
    "deferredtaxliabilityasset": "-null",
    "deferredtaxliabilityassetcontinuingoperations": 191808,
    "deferredtaxrelatingtoitemschargedorcrediteddirectlytoequity": -148130,
    "deferredtaxassetnotrecognisedrevenuetaxlosses": "null",
    "increasedecreaseindeferredtaxliabilityasset": "null",
    "netdeferredtaxassetnotrecognised": "null",
    "cash": "null",
    "weightedaverageinterestrateondeposits": 0.0115,
    "restricteddeposits": 119000,
    "othernoncurrentfinancialassets": 119000,
    "otherfinancialassets": 119000,
    "restricteddepositmaturitydate": "June 3, 2023",
    "effectiveinterestrateondeposits": 0.0195,
    "othercurrentreceivables": 42483,
    "tradeandothercurrentreceivablesbeforetax": 42483,
    "gstreceivables": 21877,
    "currentprepayments": "null",
    "currentaccruedincomeincludingcurrentcontractassets": 190,
    "othercurrentassets": "null",
    "nameofsubsidiary": "Bionomics Inc",
    "principalactivity": "Asset owner",
    "countryofincorporation": "Australia",
    "countryofincorporationorresidenceofsubsidiary": "United States",
    "proportionofownershipinterestinsubsidiary": 1,
    "additionsotherthanthroughbusinesscombinationspropertyplantandequipment": 1544,
    "disposalspropertyplantandequipment": -34344,
    "depreciationpropertyplantandequipmentcontinuingoperation": 2681,
    "depreciationandamortisationexpensecontinuingoperations": 193358,
    "increasedecreasethroughnetexchangedifferencesgoodwill": 467379,
    "descriptionofbasisonwhichunitsrecoverableamounthasbeendetermined": "The recoverable amount of the drug development CGU is determined based on a value in use calculation which uses cash flow projections based on observable market comparables for drug compounds within the CGU over a period of twenty years covering drug discovery, development, approval and marketing, and a post-tax discount rate of 17% (2021: 15%).",
    "descriptionofdiscountratesappliedtocashflowprojections": 0.17,
    "increasedecreasethroughnetexchangedifferencesintangibleassetsotherthangoodwill": -709404,
    "intangibleassetsandgoodwill": "null",
    "incomefromcontinuingoperationsattributabletoownersofparent": 913373,
    "profitlossattributabletoownersofparent": 913373,
    "tradeandothercurrentpayablestotradesuppliers": "null",
    "accrualsclassifiedascurrent": "null",
    "averagecreditperiodonpurchasesofgoods": "45 days",
    "gainslossesonexchangedifferencesontranslationrecognisedinprofitorloss": "null",
    "leaseliabilities": 693623,
    "repayments": -174218,
    "interestelementofleasepaymentscontinuingoperations": 26872,
    "cashoutflowforleases": 201090,
    "undiscountedoperatingleasepaymentstobereceived": "null",
    "currentprovisionsforemployeebenefits": 409320,
    "noncurrentprovisionsforemployeebenefits": 10460,
    "numberofsharesissued": "null",
    "issuedcapitalordinaryshares": "null",
    "numberofshareoptionsexercisedinsharebasedpaymentarrangement": "null",
    "issueofordinarysharesonexerciseofoptions": 27200,
    "numberofordinarysharesissueonexerciseofwarrants": "null",
    "issueofordinarysharesonexerciseofwarrants": 480000,
    "transferfromsharebasedpaymentsreserveasresultofoptionsandwarrantsbeingexercised": 327760,
    "issueofordinarysharesinipoandnasdaqlistingvalueshares": "null",
    "issueofordinarysharesinipoandnasdaqlistingvalue": "null",
    "weightedaverageshareprice2019": 0.15,
    "parvaluepershare": 0.09645,
    "weightedaverageexercisepriceofshareoptionsexercisedinsharebasedpaymentarrangement2019": 0.0136,
    "exercisepriceperwarrantsexercised": 0.06,
    "numberofordinarysharesissuedinusipoandnasdaqlisting": "null",
    "descriptionofordinarysharesvotingrights": "every holder of ordinary shares present at a meeting in person or by proxy, is entitled to one vote and upon a poll each share is entitled to one vote",
    "descriptionofconversionofoptionexercised": "When exercised, each option is convertible into one ordinary share.",
    "numberofotherequityinstrumentsexercisableinsharebasedpaymentarrangement": "null",
    "weightedaverageremainingcontractuallifeofoutstandingshareoptions2019": 1.16,
    "numberofotherequityinstrumentsexercisedorvestedinsharebasedpaymentarrangement": "null",
    "weightedaverageexercisepriceofotherequityinstrumentsexercisedorvestedinsharebasedpaymentarrangement2019": 0.06,
    "numberofoutstandingshareoptions": "null",
    "numberofshareoptionsgrantedinsharebasedpaymentarrangement": "null",
    "numberofshareoptionsexpiredinsharebasedpaymentarrangement": "null",
    "weightedaverageexercisepriceofshareoptionsoutstandinginsharebasedpaymentarrangement2019": 0.16,
    "weightedaverageexercisepriceofshareoptionsgrantedinsharebasedpaymentarrangement2019": 0.18,
    "weightedaverageexercisepriceofshareoptionsexpiredinsharebasedpaymentarrangement2019": 0.42,
    "dateofgrantofsharebasedpaymentarrangement": "26-Aug-20",
    "exercisepriceofoutstandingshareoptions2019": 0.06,
    "descriptionofriskfreeinterestrateshareoptionsgranted": 0.0043,
    "descriptionofexpectedvolatilityshareoptionsgranted": 1.05,
    "sharebasedpaymentsarrangementexpirationdate": "26-Aug-23",
    "numberofotherequityinstrumentsoutstandinginsharebasedpaymentarrangement": "null",
    "numberofotherequityinstrumentsexpiredinsharebasedpaymentarrangement": "null",
    "weightedaverageexercisepriceofotherequityinstrumentsoutstandinginsharebasedpaymentarrangement2019": 0.06,
    "weightedaverageexercisepriceofotherequityinstrumentsexpiredinsharebasedpaymentarrangement2019": 0.57,
    "reserveofexchangedifferencesontranslation": "null",
    "reserveofsharebasedpayments": "null",
    "tradereceivables": "null",
    "financialassets": "null",
    "tradeandotherpayables": "null",
    "financialliabilities": "null",
    "foreigncurrencysensitivityrate": 0.1,
    "monetaryitemsnet": "null",
    "otherintangibleassets": "null",
    "nonmonetaryitemsnet": "null",
    "foreigncurrencyrisk": "null",
    "gainslossesonexchangedifferencesontranslationrecognisedinequity": 18815,
    "weightedaverageeffectiveinterestrate": 0.0356,
    "tradeandotherpayablesundiscountedcashflows": "null",
    "grossleaseliabilities": 744580,
    "nonderivativefinancialliabilitiesundiscountedcashflows": "null",
    "contingentconsiderationrecognisedasofacquisitiondate": "null",
    "descriptionofvaluationtechniquesusedinfairvaluemeasurementliabilities": "Discounted cash flow",
    "descriptionofinputsusedinfairvaluemeasurementliabilities": "Discount rate of 25% (pre-tax) and probability adjusted revenue projections.",
    "descriptionofrelationshipofunobservableinputstofairvaluemeasurementliabilities": "The higher the discount rate, the lower the value.  The higher the possible revenue the higher value.",
    "increasedecreaseinfairvaluemeasurementliabilities": 936354,
    "keymanagementpersonnelcompensationshorttermemployeebenefits": "null",
    "keymanagementpersonnelcompensationpostemploymentbenefits": 69039,
    "keymanagementpersonnelcompensationotherlongtermbenefits": 22241,
    "keymanagementpersonnelcompensationsharebasedpayment": "null",
    "keymanagementpersonnelcompensation": "null",
    "operatingleaseterm": "4 years",
    "expirydateofsubletareasfacility": "July 12, 2021",
    "noncancellableoperatingleasecommitments": 18568,
    "auditorsremunerationforauditservices": 969726,
    "auditorsremuneration": 969726,
    "adjustmentsfordepreciationandamortisationexpense": "null",
    "adjustmentsforlossesgainsondisposalofnoncurrentassets": 1827,
    "adjustmentsforfairvaluegainslosses": 936354,
    "adjustmentsforunrealisedforeignexchangelossesgains": 738423,
    "interestreceivedclassifiedasoperatingactivities": 9869,
    "adjustmentsfordecreaseincreaseintradeaccountreceivable": -39148,
    "adjustmentsfordecreaseincreaseinresearchanddevelopmentincentivereceivable": "-null",
    "adjustmentsfordecreaseincreaseinotherassets": -600285,
    "adjustmentsforincreasedecreaseintradeaccountpayable": 979902,
    "adjustmentsforprovisions": 41062,
    "adjustmentsfordeferredtaxexpense": -191808,
    "basicearningslosspershare": -0.02,
    "dilutedearningslosspershare": -0.02,
    "weightedaverageshares": "null",
    "dilutiveeffectofshareoptionsonnumberofordinaryshares": "null",
    "dilutiveeffectofconvertibleinstrumentsonnumberofordinaryshares": "null",
    "numberofpotentialantidilutiveordinarysharesexcludedfromcomputationoflosspershare": "-null",
    "adjustedweightedaverageshares": "null",
    "increasedecreaseincontingentconsiderationassetliability": 936354,
    "rentguarantee": 119000,
    "expectedreimbursementotherprovisions": 22000,
    "explanationofpossibilityofreimbursementcontingentliabilities": "The Group has a consultancy agreement with Dr Errol De Souza who is paid US$43,750 per month (plus reimbursement of health care benefits of up to US$22,000 per year), plus a short-term incentive/bonus potential of 60% of fixed remuneration as assessed by the independent non-Executive directors against agreed financial, strategic and operational targets, for performance exceeding such applicable performance criteria the annual bonus may be increased up to 100% of Base Salary."
  }
]